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Survivin is an essential chromosomal passenger protein required 
for mitotic progression. It is also an inhibitor of apoptosis and 
can prevent caspase-mediated cell death. In addition, survivin 
levels are elevated in cancer cells where its presence correlates with 
increased resistance to chemo- and radio-therapy, which makes it 
an attractive target for novel anti-cancer strategies. Interestingly, 
survivin is phosphorylated by the mitotic kinase, cdk1, and a non-
phosphorylatable form, survivinT34A, cannot inhibit apoptosis. 
Here we rigorously test the ability of survivinT34A and its corre-
sponding phosphomimetic, survivinT34E, to promote cell viability 
through survivin’s dual roles. The effects of these mutations are 
diametrically opposed: survivinT34A accelerates cell proliferation 
and promotes apoptosis, whereas survivinT34E retards growth and 
promotes survival. Thus the phosphorylation status of survivin at 
T34 is pivotal to a cell’s decision to live or die.
Introduction
In normal cells survivin is expressed during G2/M and is essential 
for mitosis and cytokinesis. When overexpressed in tumors, however, 
it is present throughout the cell cycle. Survivin expression confers 
resistance to irradiation and chemotherapy,1-3 and correlates with 
refractory tumors in the clinic.4,5
In addition to its role in mitosis, survivin is a member of the 
inhibitor of apoptosis family, IAP.6 Although survivin undoubt-
edly suppresses caspase activity, how this is achieved is unclear with 
evidence for7 and against,8 direct caspase interaction. Survivin immu-
noprecipitates with cdk1 during mitosis,9 and is phosphorylated by 
it at threonine 34.10 T34 lies within the IAP-specific baculovirus 
inhibitor of apoptosis repeat domain and mutation of T34 to a non-
phosphorylatable alanine abolishes survivin’s cytoprotective activity 
and decreases its stability.10-12 Consistent with this, suppression of 
T34 phosphorylation by cdk1 inhibition also enhances apoptosis.12 
Intriguingly, survivin is the only IAP phosphorylated by cdk1. Thus, 
together with its mitotic function, the hypothesis that survivin-cdk1 
plays a central role in determining whether a cell should live or die at 
this critical juncture is attractive, see O’Connor et al. (2000).
While it is known that survivinT34A supports growth but cannot 
inhibit apoptosis,13 the functional repertoire of the corresponding 
phosphomimetic, survivinT34E has not been characterized. Here we 
examine whether these mutants can support life and inhibit death in 
cultured human cells. Our data show that modification of T34 both 
negatively and positively impacts on survivin function and is pivotal 
in balancing life and death at the cellular level.
Results and Discussion
Survivin T34 mutants have opposing effects on cell proliferation 
rates. Proliferation of HeLa cells stably expressing GFP, survivin-
GFP, survivinT34A-GFP or survivinT34E-GFP was monitored at 
24 h intervals over 4 days (Fig. 1A). Cells expressing GFP alone 
and survivin-GFP (WT) grew with similar kinetics. In contrast, 
cells expressing survivinT34A-GFP (T34A) grew two fold faster than 
controls, and cells expressing survivinT34E-GFP (T34E) grew 2.5 
fold slower.
Survivin T34 mutants localize normally during mitosis. We 
next asked whether these versions localize correctly during mitosis. 
As for survivin-GFP both mutant forms localized to the centrom-
eres (prometaphase-metaphase), midzone microtubules (anaphase) 
and midbody (cytokinesis) when endogenous survivin was present 
(Fig. 1B). However, in addition, survivinT34A-GFP appeared to 
track along the anaphase spindle, rather than being confined to the 
region of microtubule overlap, and was sometimes present at the 
centrosome. Our T34A data are in agreement with refs.13,14 The 
localization of survivinT34E-GFP is consistent with the localization of 
T34-phosphorylated as described by O’Connor et al. (2000), using 
phosphospecific antibodies, lending credence to survivinT34E as a 
phosphomimetic.
T34A, but not T34E, supports growth after depletion of endog-
enous survivin. To ascertain whether these forms of survivin could 
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support cell proliferation in the absence of endogenous 
survivin, asynchronous cultures were treated with control 
or survivin specific siRNA, see.15 SurvivinT34A-GFP, but 
not survivinT34E-GFP, supported cell proliferation after 
survivin depletion (Fig. 2A; depletion was confirmed by 
immunoblotting, data not shown). Next the number 
of mitotic cells was monitored by immunostaining 
with anti-phospho-H3ser10 antibodies. Consistent with 
the growth curves no change in the mitotic index was 
observed in survivinT34A-GFP cells. However, mitotic 
cells were rarely seen in the survivinT34E-GFP popu-
lation even without survivin depletion (Fig. 2B). In 
addition, the incidence of multinucleation revealed 
that only survivinT34A-GFP substituted for loss of 
endogenous survivin as assessed by immunofluorescence 
(Fig. 2C), and confirmed by FACS analysis (Fig. 2D). 
Note that DNA-FACS profiling does not distinguish 
between binucleated and G2/M cells, thus although 
there are fewer mitotic survivinT34E-GFP cells, as more 
are multinucleated (or in G2), the control survivinT34E-
GFP population has an apparently normal distribution. 
Importantly, upon survivin depletion the FACS profile 
remained normal for survivinT34A-GFP cells, but 
the number of 4N cells significantly increased in 
the survivinT34E-GFP population, suggesting that 
cell division failed.
To determine the fate of cells expressing only the 
ectopic form of survivin cells were imaged for 48 h 
from 24 h post-RNAi (Fig. 3A and B). While 96% 
of survivin-GFP and 95% of survivinT34A-GFP 
cells executed mitosis normally, cells expressing 
survivinT34E-GFP had a number of fates: 6.5% 
completed mitosis, 14.6% persisted in mitosis for 
the duration of filming and 15.5% exited mitosis 
inappropriately yet lived. The majority (46.3%) 
failed mitosis and died, and the remainder (17.1%) 
exited mitosis, but failed to divide. Thus consistent 
with Lens et al. (2006), survivinT34A-GFP can 
restore survivin’s mitotic function. However, our 
data extends this observation demonstrating that 
the corresponding phosphomimetic is mitotically 
incompetent, thus we conclude that phosphoryla-
tion at T34 inhibits mitosis.
Localization of CPPs and BubR1 in T34E 
cells. For successful cell division the complete chro-
mosomal passenger complex is required. We next 
examined the localization of the CPPs aurora-B 
and borealin during mitosis in cells expressing only 
the ectopic forms. Like survivin-GFP (Fig. 3C), 
Figure 1. Cell cycle characteristics of stable cell lines. 
(A) Proliferation of HeLa cells stably expressing the constructs 
indicated. The mutation T34A accelerated growth, while 
T34E reduced it. (B) Cells expressing the versions of survivin-
GFP (green) indicated were fixed and immunoprobed to 
reveal microtubules (red), and chromosomes (blue). These 
mutants localised normally although survivinT34A-GFP accumu-
lated additionally at the centrosomes and along the anaphase 
microtubules (arrow). Bars 5 μm.
Figure 2. Repertoire of T34 mutants in the absence of endogenous survivin. Endogenous 
survivin was depleted by siRNA in the lines indicated. (A) Cell proliferation was assessed over 
72 h after incubation with control (triangles) or survivin specific (circles) siRNA. Clearly survivin-
T34A-GFP supported cell growth while survivinT34E-GFP did not. (B) Mitotic staging was assessed 
by immunofluorescence imaging using anti-phospho-H3 antibodies. (C) Multinucleation was 
assessed by immunostaining for microtubules and DNA. (D) For FACS analysis cells were 
stained 48 h post-RNAi with propidium iodide to assess DNA content. After survivin depletion 
the number of 4N cells increased in the survivinT34E-GFP population, while survivinT34A-GFP 
cells were unaffected.
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with Lens et al. (2006), who showed that survivinT34A-GFP was 
mitotically competent, able to recruit borealin, aurora-B and BubR1 
to the centromeres/kinetochores, and could elicit the spindle check-
point in response to paclitaxel. Lens et al. (2006) also suggested 
that survivinT34A-GFP could act as a dominant negative, although 
in their hands the cell cycle was unaffected by its overexpression.13 
While we concur that the cell cycle distribution remains the same 
in these cells, Figure 1 suggests that survivinT34A-GFP expedites the 
cell cycle.
T34E enhances survivin’s cytoprotective activity. Having estab-
lished that T34 mutations affect the rate of cell proliferation, we 
asked whether these versions affected survivin’s anti-apoptotic activi-
ties. Overexpression of survivin-GFP protects cells against apoptosis 
induced by TRAIL,2,3 and the fact that T34A abrogates this function 
is established.10 Here asynchronous cells were treated with TRAIL 
for 15, 30, 45 or 60 minutes: note that endogenous survivin was 
present in these experiments. As expected, survivin overexpression 
protected cells against apoptosis (Fig. 4A). Although survivinT34A-
GFP can induce spontaneous apoptosis in cancer cells,17,18 we 
survivinT34A-GFP localized to the centromeres in prometaphase 
after survivin RNAi (Fig. 3F), and efficiently recruited borealin and 
aurora-B (Fig. 3G, and data not shown). In stark contrast, in the rare 
mitotic survivinT34E-GFP cells observed, chromosomes were scat-
tered in pseudoprometaphase and survivinT34E-GFP was unable to 
bind to centromeres (Fig. 3I), and neither aurora-B nor borealin was 
recruited (Fig. 3J, and data not shown). To ascertain whether centro-
meric binding of survivinT34E-GFP failed due to altered affinity 
for its mitotic partners, we performed GST-pull downs with CPPs 
(Fig. 3L). Consistent with the interdependence of their localization 
both survivinT34A-GFP and survivinT34E-GFP were able to bind 
aurora-B, borealin, and survivin, indicating that mutation of T34 
does not affect the integrity of the CPP complex.
Depletion of survivin compromises the spindle checkpoint by 
destabilising BubR1 at the kinetochores.15,16 Hence we observed 
BubR1 in these lines after depletion of endogenous survivin. BubR1 
bound to the kinetochores in the presence of either survivinT34A-GFP 
or survivinT34E-GFP indicating that the tension-spindle checkpoint 
is intact in each case (Fig. 3E, H and K). Our data are consistent 
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Figure 3. T34E inhibits mitosis. Cells were followed by time-lapse microscopy. Survivin-GFP (96%) and survivinT34A-GFP (95%) expressing cells completed 
mitosis normally, while survivinT34E-GFP had a number of different fates, as depicted in (A) and quantified in (B): the majority (46.3%) failed to align their 
chromosomes then died (red); 14.6% persisted in mitosis (green); 15.5% failed to align their chromosomes then exited mitosis but lived (yellow); 6.5% 
divided normally (blue); and 17.1% exited mitosis but failed cytokinesis (black). (C–K) Immunolocalisation of survivin, borealin and BubR1 48 h post-
survivin depletion. SurvivinT34A-GFP localised normally when expressed alone, and localisation of borealin and BubR1 was unimpaired. However, neither 
survivinT34E-GFP, nor borealin was centromeric, although BubR1 was still present. Bars 5 μm. (L) GST-pull down assay to assess whether binding to in vitro 
translated CPPs. As shown in the autorad (35S-methionine), all versions bound wild type survivin, aurora-B and borealin.
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The caspase-8 activity profiles were similar to those of caspase-3: 
caspase-8 activity peaked earlier, as expected for an “initiator” caspase 
(Fig. 4B).
As T34 is phosphorylated by cdk1 during mitosis,10 we consid-
ered whether inhibition of apoptosis was more apparent in mitosis 
than in other cell cycle stages. Cells were arrested in G1 by 16 h 
saw only a modest elevation in the basal level of caspase-3 activity 
without TRAIL (Fig. 4A, time 0). Nevertheless, survivinT34A-GFP 
greatly sensitizes cells to TRAIL, as apoptosis occurred more rapidly 
than in the control population. By far the most striking observa-
tion was the ability of survivinT34E-GFP lysates to suppress, almost 
completely, TRAIL-mediated apoptosis.
Figure 4. Mutation of T34 alters survivin’s cytoprotection. (A) Apoptosis was induced in asynchronous cultures by exposure to TRAIL for the indicated times, 
lysates prepared and caspase-3 activity assessed by cleavage of the tetrapeptide Ac-DEVD-AMC. Apoptosis was induced more rapidly in survivinT34A-GFP 
lysates than from control (GFP) cells. SurvivinT34E-GFP lysates almost completely inhibited apoptosis. (B) Caspase-8 activity was similar but occurred earlier. 
(C–E) Caspase-3 activity assays were performed in synchronised populations, arrested in G1 (C), S-phase (D) or mitosis (E), after treatment with TRAIL for 0, 
30 or 60 minutes (key as above). The most profound difference in survivinT34A-GFP and survivinT34E-GFP anti-apoptotic activities was seen in mitotic cells. 
(F) Cells were exposed to increasing doses of X-irradiation, allowed to grow for 7–9 days, and colonies of >50 cells counted. Surviving fractions are plotted 
logarithmically. SurvivinT34A-GFP cells conferred no resistance to X-rays, but survivinT34E-GFP cells showed extraordinary resistance to this genotoxic stress.
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the mitotic index, fixed cells were probed with anti-phosphoH3ser10 
or anti-tubulin.
FACS profiling. Cells were harvested in ice cold PBS, fixed in 
70% ethanol at -20°C for 2 h. They were then washed and treated 
with 100 μg/ml Rnase and stained with 100 μg/ml propidium iodide 
in PBS to assess DNA content, and held at 25°C for 15 minutes 
prior to analysis. Samples were analysed using a FACS Canto (Becton 
Dickinson).
RNAi. Cells were seeded at 2 x 104 per well (24 well plate) in 
anti-biotic free media then transfected with 60 pmol of control or 
survivin specific siRNA (Ambion) using HyperFect (Qiagen), as 
described in.2 Constructs were rendered resistant to RNAi-targetting 
by introduction of a silent mutation, G54C.20,21
Immunoblotting. Immunoblot analysis was performed as 
described in Colnaghi et al. (2006). Antibodies used: anti-survivin 
(1:750, rabbit, Ab469, Abcam) and anti-tubulin (B512, 1:2000, 
Sigma). Signal intensity was detected using horseradish peroxidase 
conjugated secondary antibodies (1:2000; Dakocytomation), ECL 
and X-ray film (both G.E. Healthcare) or by Phosphoimaging 
(Storm).
Time lapse imaging. Cells were grown in 35 mm glass-bottomed 
Willco dishes in phenol-red free CO2 independent medium 
(Invitrogen), supplemented as for DMEM. From 24–72 h post-
transfection with siRNA cells were monitored at 20x using a Leica 
DMIRB inverted microscope with Simple PCI software (Digital 
Pixel). Images were prepared as JPEGs using Photoshop.
GST-pull down assays. Expression of GST-tagged proteins 
was induced in BL21 cells by the addition of 0.1 mM IPTG, and 
purified protein bound to glutathione sepharose 4B beads (G.E. 
Healthcare). In vitro translation was performed (90 minutes, 30°C) 
with pcDNA3.1 survivin, aurora-B or borealin using a TNT T7 kit 
(Promega), with 35S methionine (G.E. Healthcare) as tracer. Beads 
and translated product were incubated for 1 h at 4°C, then analysed 
by SDS-PAGE and autoradiography.
TRAIL treatment and apoptosis assay. Cells were seeded at 5 x 
104 per well in 24-well plates. The following day they were treated 
at 15 or 30 minute intervals with 250 ng/ml recombinant TRAIL 
(PeproTech EC Ltd.,). Lysates were prepared in 200 μl MPER buffer 
(Pierce) containing 1 mM EDTA, 1 μg/μl pepstatin A, 1 mM AEBSF 
and centrifuged to remove debris. Caspase 3 activity was assessed 
spectoscopically by cleavage of the fluorogenic tetrapeptide substrate, 
Ac-DEVD-AMC (BioMol), as described previously.2,3 Caspase-8 
activity was assessed similarly using Ac-IETD-AMC (BioMol).
Clonogenic survival assays. Cells were seeded at low density in 
Petri dishes and irradiated 2 h later at 0, 2.5, 5 or 7.5 Grays using 
an Hs-X-Ray System (A.G.O Installations Ltd., Reading, UK). 
Seven-ten days post-irradiation cultures were stained with methylene 
blue (1 h, 25°C), and colonies of >50 cells counted. 
Statistical analysis. Comparisons among all groups were performed 
in Microsoft Excel with the one-way analysis of variance test. Values 
of p < 0.05 were considered significant.
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treatment with 500 μM mimosine; S-phase by 16 h treatment 
with 2 mM thymidine; and M-phase by 16 h treatment with 
0.2 μg/ml colcemid, then exposed to TRAIL for 30 or 60 minutes, 
and caspase-3 activity assayed on the lysates (Fig. 4C–E). Caspase-3 
activity was highest in mitotically arrested control and survivinT34A-
GFP cells, while survivinT34E-GFP again ablated caspase-3 activity 
(Fig. 4E).
Next we exposed cells to increasing doses of X-irradiation and 
assessed clonogenic survival 7–9 days later. Cells expressing survivin-
GFP were more resistant to irradiation than control (GFP) cells 
(Fig. 4F). This resistance was abolished by the mutation T34A. 
Strikingly, however, the phosphomimetic mutation, T34E, greatly 
enhanced resistance, with an astounding 55% of the popula-
tion surviving a genotoxic insult of 7.5 Gy. Cytoprotection by 
survivinT34E-GFP was previously observed after UV irradiation of 
melanoma cells,1 however, as no comparison was made to wild type, 
the remarkable enhancement of survivin’s anti-apoptotic activity by 
this pseudophosphorylation was not apparent. Augmentation of 
survivin’s anti-apoptotic activity by cdk1-mediated phosphorylation 
parallels the regulation of caspase-9, which is inhibited from initi-
ating apoptosis from mitosis when phosphorylated by cdk1.19 Thus 
it will be interesting to determine whether these proteins operate 
synergistically in promoting survival.
In conclusion, when survivin is unable to be phosphorylated at 
T34, growth is accelerated, but cells are not protected against death-
inducing stimuli. In contrast, pseudophosphorylation of T34 retards 
growth, and does not support mitosis when expressed alone, however, 
it significantly enhances cell viability in response to death-inducing 
stimuli. Therefore survivinT34A-GFP is dominant in proliferation, 
and dominant negative during apoptosis, while survivinT34E-GFP 
is dominant negative in mitosis and dominant in apoptosis. Since 
survivin is phosphorylated on this residue in vivo, our data suggest 
that phosphorylation of T34 is a protective modification that 
preserves cell viability with incredibly high efficiency. Our data also 
suggest that like aurora-B,20 cdk1 negatively regulates survivin during 
mitosis and T34-phosphorylation must be reversed, or the protein 
eliminated, in order for cells to complete division. Thus survivin’s 
dual functions can be separated, and exaggerated, by modification of 
T34, which is pivotal in cellular decisions over life and death.
Materials and Methods
Unless otherwise stated, all chemicals were obtained from Sigma-
Aldrich and tissue culture products from Invitrogen.
Cell lines. HeLa cell lines were established by FuGene-6 (Roche) 
mediated transfection of pcDNA3.1 constructs encoding GFP, 
survivin-GFP, survivinT34A-GFP or survivinT34E-GFP, followed by 
G418 selection and FACS sorting. Cells were cultured as described 
in Colnaghi et al. (2006). Cell proliferation assessed by trypan blue 
exclusion using a haemocytometer.
Fluorescence microscopy. Cells were fixed with 4% formalalde-
hyde, permeabilized with 0.15% Triton then probed with primary 
antibodies: anti-borealin (1:200, in-house), anti-BubR1 (1:500, 
provided by Stephen Taylor), anti-phosphoH3ser10 (1:200, Upstate), 
or anti-tubulin (1:2000, B512), followed by texas red conjugated 
secondary antibodies (1:200, Vector Labs). All cells were counter-
stained with DAPI in Vectashield mounting medium (Vector Labs). 
Images were prepared as described in Colnaghi et al. (2006). To assess 
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